Companies · Biotech

Epoch Biotech, LLC

DOVER · Biotech · refined from filed group “Other Technology

Diligence memoA one-page analyst read on Epoch Biotech, LLC — recommendation, valuation, rhythm, risks.
$1.0M
Total raised · real
2
Rounds
0.6×
Latest step-up
Top 28%
Sector rank · raised
Pre-Seed
Latest stage · inferred · Thu May 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Epoch Biotech, LLC has raised $1.0M over 2 rounds; too few niche peers to rank its valuation yet.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Quiet
  • Last raise 13 mo ago; this sector typically re-raises about every 11 months.
  • Slightly overdue versus sector cadence.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Issuer-vehicle patternmedium confidence

Epoch Biotech, LLC behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Company-like
No recurring-offering pattern strong enough to override normal financing interpretation.
Lifecycle
3.3 yr record
Peak capital year was 2023 with $720K across 1 filings.
Market position
ahead of 73% of Biotech peers
Capital scale is ahead of 73% of Biotech peers; modeled value is above 69% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Normal applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Needs review
Row-level filing totals differ from canonical totals, so amendment/superseded filtering should be checked.
What triggered this
  • Legal name looks like an issuer vehicle rather than a product company.
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in 2023: $720K across 1 filings.
  • Largest single filing was $720K on 2023-03-19.
  • Filing rows sum to $1.4M, while canonical raised total is $1.0M; likely amendments/superseded rows are mixed into the detail view.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
  • Canonical filtering should be tightened before using row-level totals for diligence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotech

Epoch Biotech, LLC is one of 233 Biotech companies tracked from DOVER. By capital raised it ranks in the upper tier (ahead of 73% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

biotech

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
3
Investors (latest)
2022
Year incorporated
2025-05-22
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$2.5M$5.0M$7.5M$10MPre-Seed · 2023-03-19 Raised $720K (real) Modeled valuation $7.4M (est)$720K$7.4MPre-Seed2023Pre-Seed · 2025-05-22 Raised $300K (real) Modeled valuation $797K (est)$300K$797KPre-Seed2025Pre-Seed · 2025-05-22 Raised $240K (real) Modeled valuation $638K (est)$240K$638KPre-Seed2025Pre-Seed · 2025-05-22 Raised $140K (real) Modeled valuation $372K (est)$140K$372KPre-Seed2025+$300K+$240K+$140KCumulative $1.4M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$720K · 2023
Pre-Seed extension$300K · 2025
Pre-Seed extension$240K · 2025
Pre-Seed extension$140K · 2025

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$797K
Base estimate est.
$160K
Conservative case
$2.0M
Upside case
$1.7M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Pre-Seeda round under $1.0M). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $7.4M · 2023-03-192023Pre-Seed · modeled $797K · 2025-05-22Pre-Seed · modeled $638K · 2025-05-22Pre-Seed · modeled $372K · 2025-05-222025
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
24%
Survival probability
10% low · 44% high
1.86×/yr
Annual markup
2.52×/yr upside case
1.1 yr
Elapsed time used
1.1 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
9 mo
Avg between rounds
$469K/yr
Capital velocity
3.3 yr
On record since
2023
First round
4
Rounds on file
How it compares to the market

Benchmarked against 233 companies in Biotech. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.1× of median
This company$1.0M
Sector median$7.8M
Latest round — vs other Pre-Seed rounds in sector (real $, this stage) 0.4× of median
This company$140K
Sector median$315K
Modeled value — vs sector median (estimate, all stages) 0.0× of median
This company$797K
Sector median$56.2M

Raised more than 73% of sector peers (real $). Modeled value above 69% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Pre-Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful.

This companyCohort peer
$100K$1.0M$10.0M$100K$1.0M$10.0MCapital raised (log)Upstream Biotechnology, Inc. · Pre-Seed Raised $625K · modeled $1.4M (est)Corami Biotech Inc. · Pre-Seed Raised $210K · modeled $329K (est)Epoch Biotech, LLC (this company) Raised $1.0M · modeled $797K (est)Epoch Biotech, LLC
CompanyStageRaised · realValue · estvs peer med.
Upstream Biotechnology, Inc.Pre-Seed$625K$1.4M1.77×
Epoch Biotech, LLC this companyPre-Seed$1.0M$797K1.00×
Corami Biotech Inc.Pre-Seed$210K$329K0.41×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$720K2023-03-19$4.0M$7.4M90%
Pre-Seed$300K2025-05-22$1.7M$797K90%
Pre-Seed$240K2025-05-22$1.3M$638K90%
Pre-Seed$140K2025-05-22$778K$372K90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$720K2023-03-19
    • First recorded raise — entered as Pre-Seed.
    • 10 investors on this round.
  2. Pre-Seed$300K2025-05-22
    • Raised again after 26 mo — slower than the ~11 mo sector norm.
    • Round 2.4× smaller than the prior — bridge or down round.
    • 5 investors on this round.
  3. Pre-Seed$240K2025-05-22
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 4 investors on this round.
  4. Pre-Seed$140K2025-05-22
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.7× smaller than the prior — bridge or down round.
    • 3 investors on this round.
Intelligence
2026 ~Q1
Modeled next raise · ~9mo cadence
$140K
Modeled next size est.range $140K$224K
0.6×
Last step-up
$469K/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Michael Aceti3 other2023-03
Michael R. Aceti2025-05
Registry & provenance

Epoch Biotech, LLC is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1984545
SEC CIK
2022
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
X1 Biotech Inc.BiotechPre-Seed$100K$691Knetwork1 shared operator · same sector · same stage
Antlia Bioscience, Inc.BiotechPre-Seed$887K$12.4Msame sector · same stage
Upstream Biotechnology, Inc.BiotechPre-Seed$625K$1.4Msame sector · same stage
Exponential Genomics Inc.BiotechPre-Seed$600K$33.1Msame sector · same stage
CMTx Biotech, Inc.BiotechPre-Seed$500K$27.6Msame sector · same stage
Empire Genomics Corp.BiotechPre-Seed$500K$16.7Msame sector · same stage
Innovation1 Biotech Inc.BiotechPre-Seed$487K$1.8Msame sector · same stage
Kingsmore Biotech, LLCBiotechPre-Seed$478K$26.4Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Ark Biotech Inc.BiotechSeries A$46.0M81%
Spearhead Bio, Inc.Biotech / PharmaSeed$3.6M81%
Stem Biotech LLCBiotechnologySeries C$4.1B81%
Meridian Biotech, LLCBiotechSeed$88.1M80%
MAIA Biotechnology, Inc.BiotechnologySeries A$3.9M80%
Empire Biotechnologies, Inc.Biotech / PharmaPre-Seed$5.6M80%
Archean Biologics, Inc.Biotech / PharmaSeries A$100.7M80%
Sistema.bio, Inc.Biotech / PharmaSeries A$21.5M80%
Frequently asked
How much funding has Epoch Biotech, LLC raised?
Epoch Biotech, LLC has raised approximately $1.0M in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is Epoch Biotech, LLC's estimated valuation?
Provath's modeled valuation for Epoch Biotech, LLC is approximately $797K (modeled range $160K–$2.0M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Epoch Biotech, LLC at?
Epoch Biotech, LLC's latest modeled financing stage is Pre-Seed. Its most recent recorded round closed around Thu May 22.
What does Epoch Biotech, LLC do and where is it based?
Epoch Biotech, LLC operates in the Biotech sector, based in DOVER.
Explore related

See where Epoch Biotech, LLC sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Epoch Biotech, LLC, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.